KR20220044478A - 알파-케토글루타레이트의 지속 방출 조성물 - Google Patents

알파-케토글루타레이트의 지속 방출 조성물 Download PDF

Info

Publication number
KR20220044478A
KR20220044478A KR1020227000256A KR20227000256A KR20220044478A KR 20220044478 A KR20220044478 A KR 20220044478A KR 1020227000256 A KR1020227000256 A KR 1020227000256A KR 20227000256 A KR20227000256 A KR 20227000256A KR 20220044478 A KR20220044478 A KR 20220044478A
Authority
KR
South Korea
Prior art keywords
composition
ketoglutarate
release
calcium
calcium alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227000256A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 유진 페레이라
수마나 코나르
Original Assignee
폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 filed Critical 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니
Publication of KR20220044478A publication Critical patent/KR20220044478A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020227000256A 2019-06-10 2020-06-10 알파-케토글루타레이트의 지속 방출 조성물 Pending KR20220044478A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962859595P 2019-06-10 2019-06-10
US62/859,595 2019-06-10
US201962929024P 2019-10-31 2019-10-31
US62/929,024 2019-10-31
PCT/US2020/036987 WO2020252014A1 (en) 2019-06-10 2020-06-10 Sustained-release compositions of alpha-ketoglutarate

Publications (1)

Publication Number Publication Date
KR20220044478A true KR20220044478A (ko) 2022-04-08

Family

ID=73781275

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227000256A Pending KR20220044478A (ko) 2019-06-10 2020-06-10 알파-케토글루타레이트의 지속 방출 조성물

Country Status (11)

Country Link
US (1) US20220265586A1 (enExample)
EP (1) EP3980001B1 (enExample)
JP (2) JP7751291B2 (enExample)
KR (1) KR20220044478A (enExample)
CN (1) CN114126601B (enExample)
BR (1) BR112021024952A2 (enExample)
CA (1) CA3142494A1 (enExample)
DK (1) DK3980001T3 (enExample)
IL (1) IL288782A (enExample)
TW (1) TWI869410B (enExample)
WO (1) WO2020252014A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7499259B2 (ja) * 2018-09-25 2024-06-13 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
MX2024008182A (es) * 2021-12-29 2024-09-24 Jrs Pharma Gmbh & Co Kg Lubricante para productos farmacéuticos y nutracéuticos.
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
CN100400042C (zh) 1999-12-03 2008-07-09 聚合化学股份公司 制备生物利用度改善的麦角生物碱持续释放药物组合物的方法及其组合物
JP4169596B2 (ja) * 2000-12-20 2008-10-22 アルコン、インコーポレイテッド 白内障を液化破壊により取り除くための溶液
US20060029668A1 (en) 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
CA2574597A1 (en) * 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
FR2967578B1 (fr) 2010-11-18 2012-12-28 Advicenne Pharma Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
MX377119B (es) * 2013-06-06 2025-03-07 Amip Llc Un sistema de dosis no alimenticia suministrable oralmente que comprende hierro y un agente.
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN108653221B (zh) * 2015-06-03 2021-09-07 南京三迭纪医药科技有限公司 药品剂型及其使用
EP3518915A4 (en) * 2016-09-30 2020-04-15 The Regents of the University of California ALPHA KETOBUTYRATE, ALPHA KETOGLUTARATE AND 2-HYDROXYBUTYRATE FOR STIMULATING HAIR GROWTH
KR20180062063A (ko) * 2016-11-30 2018-06-08 (주) 메티메디제약 서방형 항암용 약학 조성물
MX2017004010A (es) * 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
KR102643567B1 (ko) 2017-04-25 2024-03-05 버크 인스티튜트 포 리서치 온 에이징 수명 및 건강수명을 연장시키기 위한 제제

Also Published As

Publication number Publication date
EP3980001B1 (en) 2025-08-27
CN114126601B (zh) 2025-07-15
CN114126601A (zh) 2022-03-01
JP2025124683A (ja) 2025-08-26
WO2020252014A1 (en) 2020-12-17
TWI869410B (zh) 2025-01-11
EP3980001A4 (en) 2023-06-21
JP2022537685A (ja) 2022-08-29
US20220265586A1 (en) 2022-08-25
CA3142494A1 (en) 2020-12-17
EP3980001A1 (en) 2022-04-13
TW202112362A (zh) 2021-04-01
JP7751291B2 (ja) 2025-10-08
BR112021024952A2 (pt) 2022-02-15
IL288782A (en) 2022-02-01
DK3980001T3 (da) 2025-12-01
AU2020292278A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
AU2019268049B2 (en) Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
US10688058B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP2025124683A (ja) アルファ－ケトグルタル酸塩の持続放出組成物
CN102791258B (zh) 雷沙吉兰的延长释放制剂及其用途
KR20090045945A (ko) 제어 방출 시스템 및 이의 제조방법
CN102036656A (zh) 含有蜡的缓释制剂
AU2011222856A1 (en) Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
CA2529746A1 (en) Oral extended-release composition
JP2017149725A (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
US12178918B2 (en) Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
NO20121414A1 (no) Farmasoytiske sammensetninger omfattende hydromorfon og nalokson
US8883199B2 (en) Administration regime for N-hydroxy-4-{2-[3-(N,N-dimethylaminomethyl)benzofuran-2- ylcarbonylamino]ethoxy}benzamide
AU2012357956A1 (en) Immediate release multi unit pellet system
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
AU2020292278B2 (en) Sustained-release compositions of alpha-ketoglutarate
HK40071632A (en) Sustained-release compositions of alpha-ketoglutarate
CN113662930A (zh) 二蒽酮类化合物在制备预防和/或治疗心肌缺血性疾病及其相关病症的药物中的应用
CN101011368A (zh) 曲克芦丁的缓释制剂
EP2543363A1 (en) Sustained release pharmaceutical oral solid dosage forms of dronedarone or one of its pharmaceutically acceptable salts
CN101015535A (zh) 哌克昔林的缓释制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000